FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions

Area of Science:

• Immunology
• Gastroenterology
• Pharmacology

Background:

• Sphingosine-1-phosphate (S1P) analogue FTY720 modulates lymphocyte trafficking via S1P receptors.
• Emerging evidence suggests FTY720 possesses additional functions beyond lymphocyte homing, potentially impacting cytokine effector pathways.
• T helper type 2 (Th2) cell-mediated inflammation, characterized by IL-13 production, is a key driver of experimental colitis models that mimic human ulcerative colitis.

Purpose of the Study:

• To investigate the therapeutic and prophylactic effects of FTY720 in a murine model of Th2-mediated oxazolone-induced colitis.
• To elucidate the underlying mechanisms of FTY720 action, focusing on its impact on Th2 cytokine profiles and differentiation markers.

Main Methods:

• Oxazolone-induced colitis was established in BALB/c mice via rectal instillation.
• FTY720 was administered intraperitoneally at different time points relative to oxazolone challenge.
• Colitis severity was assessed daily, with subsequent analysis of plasma FTY720 levels, colon histology, myeloperoxidase activity, and cytokine expression (IL-13, IL-4, IL-5) in lamina propria CD4(+) T-cells, including T1/ST2 expression.

Main Results:

• FTY720 administration markedly attenuated clinical and histopathological signs of colitis, including weight loss, diarrhea, and intestinal inflammation.
• Treatment with FTY720 led to a significant reduction in the expression of key Th2 cytokines: IL-13, IL-4, and IL-5.
• FTY720 effectively inhibited the expression of GATA3 and T1/ST2, critical markers for Th2 cell differentiation and effector function.

Conclusions:

• FTY720 demonstrates significant prophylactic and therapeutic benefits in a Th2-mediated experimental colitis model.
• The therapeutic efficacy of FTY720 is associated with direct modulation of Th2 cytokine production and suppression of key Th2 differentiation markers, notably T1/ST2.
• These findings highlight FTY720 as a potential novel therapeutic agent for treating human ulcerative colitis by targeting Th2-driven inflammatory pathways.